Our aim:

The main aim of the Acellmed is to conduct commercial screening of new drugs to determine their safety and efficacy on human cardiac cells. In our research, we apply Nobel Prize awarded technology – induced pluripotential stem cells (iPSC), differentiated into cardiac cells – cardiomyocytes. Thus we create opportunities to test potential drugs directly on cardiomyocytes of patients as well as on those of healthy individuals. Our technology enables us to detect substances capable of correcting cardiomyocytes defects, which are responsible for many heart conditions. It also allows us to monitor and detect the risks of potential drugs (e.g., oncological) that may be too toxic for cardiac cells and therefore, dangerous for patients.

Generation of iPSCs lines

Differentiation of Neural Cells

Differentiation of Cardiomyocytes

Drug Screening in case of cardiotoxicity

One of the principal reasons to suspend ongoing research on new therapies is their cardiotoxicity.  Regulations require that novel, and promising therapeutic molecules shall be subjected to the rigoristic toxicity tests using traditional methods in vitro and referential animal models. Those tests, however, do not reflect the reaction of human organism on drugs fully; also, they do not allow on detection of many potentially cardiotoxic substances. Direct application of drugs onto human cardiomyocytes, on the one hand, limits the use of lab animals; on the other – it creates a unique opportunity to select and test proper medications correcting particular cardiomyocytes defects. Directly-applied drugs are, therefore, the base of personalized medicine.

Moreover, Acellmed is developing a technology of “the heart-on-the chip,” based on the use of miniaturized micro-circulation systems which will allow on investigating the interaction between different heart cell types, and in the future – also of other organs.

chip-1-1

Production line of iPSC and cardiomyocytes

In its research, Acellmed uses human peripheral blood cells (leucocytes), which effectively reprograms into iPSC; afterward, with high efficiency differentiates them into heart cells – cardiomyocytes. Hence we create iPSC bank cells from patients suffering from heart diseases (e.g., genetic primary and secondary cardiomyopathy) and healthy individuals.

Scale 20x

The film presents shrinking human cardiomyocytes obtained from induced pluripotent stem cell (iPSC).

Our customers

Business

  • Biotechnology, pharmaceutical and cosmetics

Science

  • Scientists interested in research on IPSC and cells differentiated from iPSC

Healthcare

  • Health care providers / health care institutions

Our offer

Products

  • Complete line of iPSC and cardiomyocytes
  • Conducting complete of generating iPSC and differentiated cel upon the commission of potential researchers interested in thier application

Research services

  • Research on the safety and effectiveness of potential drugs: comprehensive studies on the toxicity of selected substances – potential oncological drugs
  • Tests on drug efficacy in correcting cardiomyocytes defects, caused by functional disorder (as a result of mutations or undergoing oncological therapy)

Research on the safety and effectiveness of potenial drugs:

  • We offer the industry and health care institutions the toxicity studies, including tests on potential cardiotoxicity of the substances suspected to be an environmental threat

Our offer will enable the scientists and companies researching new drugs, on selecting safer substances, reducing unnecessary costs of preclinical trials; it may accelerate the process of introducing new drugs into the market.

Contact

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

I consent to processing of my personal data contained in the above contact form by Acellmed Ltd. with the registered seat in Zabrze, St. M. Curie-Skłodowskiej 10C, 41-800 Zabrze, to contact in connection with the application sent via the contact form. The consent may be withdrawn at any time without affecting the lawfulness of personal data processing, which was made on the basis of the consent granted before its withdrawal.

The controller of the personal data, i.e. the entity deciding on the purposes and methods of their processing, is Acellmed Ltd. with the registered seat in Zabrze (41-800), St. Marii Curie - Skłodowskiej 10c, hereinafter referred to as "Acellmed". The contact details of the data protection officer are: iod@acellmed.pl.


Privacy policy - more

Adres

ACELLMED Ltd.
St. M. Skłodowskiej-Curie 10c
41-800 Zabrze, Poland
biuro@acellmed.pl